- Home
- BBY vs JAZZ Comparison
BBY vs JAZZ Comparison
Compare BBY & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBY | JAZZ |
|---|---|---|
| Founded | 1966 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 15.0B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BBY | JAZZ |
|---|---|---|
| Price | $78.53 | $230.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 14 |
| Target Price | $76.28 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 4.8M | 810.7K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.54% | N/A |
| EPS Growth | ★ 17.76 | N/A |
| EPS | 1.31 | ★ 4.43 |
| Revenue | ★ $41,691,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $1.15 | $6.22 |
| Revenue Next Year | $1.38 | $7.68 |
| P/E Ratio | $58.92 | ★ $53.20 |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $55.10 | $105.00 |
| 52 Week High | $84.99 | $243.32 |
Technical Indicators
Market Signals| Indicator | BBY | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 73.59 | 54.77 |
| Support Level | $70.38 | $224.23 |
| Resistance Level | $84.33 | $242.66 |
| Average True Range (ATR) | 2.93 | 7.12 |
| MACD | 0.81 | -1.58 |
| Stochastic Oscillator | 98.82 | 48.45 |
Price Performance
Historical ComparisonAbout BBY Best Buy Co. Inc.
Best Buy Co Inc is a pure-play consumer electronics retailer in the USA. It has two reportable segments: Domestic and International. The Domestic and International segments have offerings in six revenue categories. Computing and Mobile Phones, Consumer Electronics, Appliances, Entertainment, Services, and Other. The company has approximately 1,068 stores throughout its Domestic and International segments. It also have vendor store-within-a-store concepts to allow closer vendor partnerships and a higher quality customer experience. The company generates majority of its revenue from the Domestic segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.